Product identification
Medicine name:
Mektix 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg
Active substance:
- Milbemycin oxime
- Praziquantel
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Milbemycin oxime12.50/milligram(s)1.00Tablet
-
Praziquantel125.00/milligram(s)1.00Tablet
Pharmaceutical form:
-
Chewable tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP54AB51
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Package description:
- Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil. Cardboard box with 12 blisters, each blister contains 4 tablets (total 48 tablets).
- Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil. Cardboard box with 1 blister of 4 tablets.
- Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil. Cardboard box with 1 blister of 2 tablets.
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Generic application (Article 13(1) of Directive No 2001/82/EC)
Manufacturing sites for batch release:
- KRKA tovarna zdravil d.d. Novo mesto
- TAD Pharma GmbH
Authorisation number:
- 47107/24-04-2025/K-0239102
Date of authorisation status change:
Reference member state:
-
Ireland
Procedure number:
- IE/V/0526/002
Concerned member states:
-
Austria
-
Belgium
-
Cyprus
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Italy
-
Latvia
-
Lithuania
-
Netherlands
-
Portugal
-
Romania
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
English (PDF)
Download Published on: 3/05/2024
Greek (PDF)
Published on: 6/05/2025
Package Leaflet
This document does not exist in this language (English). You can find it
in another language below.
Greek (PDF)
Published on: 6/05/2025